Oslo Pensjonsforsikring AS Makes New $17.64 Million Investment in Danaher Corporation $DHR

Oslo Pensjonsforsikring AS acquired a new position in shares of Danaher Corporation (NYSE:DHR) during the 1st quarter, HoldingsChannel.com reports. The institutional investor acquired 93,044 shares of the conglomerate’s stock, valued at approximately $17,641,000. Danaher accounts for approximately 2.7% of Oslo Pensjonsforsikring AS’s holdings, making the stock its 14th biggest holding.

Several other large investors also recently added to or reduced their stakes in the company. Elevated Capital Advisors LLC acquired a new position in Danaher during the fourth quarter valued at approximately $26,000. Hilton Head Capital Partners LLC bought a new stake in shares of Danaher during the 4th quarter worth $27,000. JPL Wealth Management LLC bought a new stake in shares of Danaher during the 3rd quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd grew its stake in Danaher by 71.6% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after buying an additional 53 shares during the last quarter. Finally, Main Street Group LTD bought a new position in Danaher in the 1st quarter worth $25,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

NYSE:DHR opened at $179.01 on Wednesday. The company has a quick ratio of 1.52, a current ratio of 1.87 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average price of $184.22 and a 200 day moving average price of $197.69. The firm has a market capitalization of $126.70 billion, a PE ratio of 34.62, a price-to-earnings-growth ratio of 2.48 and a beta of 0.79. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.84 by $0.10. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.11 billion. During the same period in the prior year, the business posted $0.77 earnings per share. The business’s revenue was up 5.5% compared to the same quarter last year. Research analysts anticipate that Danaher Corporation will post 8.45 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. Danaher’s dividend payout ratio is currently 30.95%.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher posted Q2 adjusted EPS of $1.94, above the $1.84 consensus, and revenue of about $6.26 billion to $6.3 billion, also ahead of estimates. Danaher Reports Second Quarter 2026 Results
• Positive Sentiment: Management raised full-year adjusted EPS guidance, showing confidence in profitability despite the softer sales backdrop. Danaher Corp (DHR) Q2 2026 Earnings Call Highlights
• Neutral Sentiment: Life Sciences was a bright spot, with stronger sales growth, but bioprocessing revenue came in weaker than expected and was cited as a drag on sentiment. Reuters: Danaher’s revenue outlook cut, biotech miss overshadow profit forecast raise
• Negative Sentiment: Investors reacted negatively to the reduced core revenue growth outlook and cautious near-term guidance, which outweighed the earnings beat and led to the stock decline. Danaher stock slips despite Q2 earnings beat, raised guidance
• Negative Sentiment: Analysts also highlighted “surprisingly soft” bioprocessing sales, reinforcing concerns that growth may slow more than expected. Danaher Plummets After One Segment Comes In ‘Surprisingly Soft’

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent analyst reports. HSBC dropped their price objective on Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Jefferies Financial Group reaffirmed a “buy” rating and issued a $245.00 price target on shares of Danaher in a research report on Tuesday, April 21st. Wolfe Research lowered Danaher from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. Argus reduced their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Finally, Weiss Ratings upgraded shares of Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $231.64.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.